Investors May Lead Capricor Therapeutics Securities Fraud Lawsuit
Law firm SBS Law reminds investors of a class action lawsuit filed against Capricor Therapeutics, alleging violations of securities laws.
The law firm Schall, Brown & Schwartz LLP (SBS) has notified investors of a class action lawsuit filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR). The lawsuit alleges that the company violated securities laws, including sections §10(b) and §20(a).
The complaint pertains to a period during which Capricor Therapeutics is accused of making misleading statements or omitting material information. This specifically relates to the company's development of a treatment for heart failure, an exosome-based therapy named for children with Duchenne muscular dystrophy. Allegations suggest the company was not sufficiently transparent regarding the results of clinical trials and the therapy's efficacy.
SBS Law is encouraging shareholders of Capricor Therapeutics who have suffered losses due to the alleged securities violations to contact the firm. The objective is to identify and appoint a lead plaintiff for the litigation. The company's stock price has experienced a significant decline, resulting in losses for investors.
The lawsuit highlights the importance of investor protection and corporate obligations to provide accurate and complete information in the financial markets. Such legal actions can lead to substantial compensation for investors if the claims are proven.